ライフサイエンスコーパス: lower respiratory tract

1 imens to check that they originated from the lower respiratory tract.

2 per respiratory infection progressing to the lower respiratory tract.

3 of novel reassortants were isolated from the lower respiratory tract.

4 ence the distribution of the inoculum in the lower respiratory tract.

5 old more than 1129 did in both the upper and lower respiratory tracts.

6 and reduced RSV loads in both the upper and lower respiratory tracts.

7 s multiple diseases throughout the upper and lower respiratory tracts.

8 and spread extensively in both the upper and lower respiratory tracts.

9 s SARS-CoV-2 infection in both the upper and lower respiratory tracts.

10 ted with a reduced risk of infections of the lower respiratory tract (31.7% vs. 39.1%; hazard ratio,

11 common anatomical site of isolation was the lower respiratory tract (58.8%), followed by superficial

12 rotection from challenge in the upper versus lower respiratory tract and bear upon live attenuated va

13 rticle aerosols of virus would penetrate the lower respiratory tract and blanket alveoli where target

14 tissue can be involved in AAV, the upper and lower respiratory tract and kidneys are most commonly an

15 bition of viral replication in the upper and lower respiratory tract and much reduced viral shedding.

16 mmunity-acquired infections of the upper and lower respiratory tract and potentially increasing morbi

17 H9 viruses infected the upper and lower respiratory tract and the majority of H9 viruses h

18 hibited limited replication in the upper and lower respiratory tract and triggered strong protective

19 PRCV has a tissue tropism for the upper and lower respiratory tracts and a cellular tropism for type

20 Pathology is pronounced in the upper and lower respiratory tract, and disease signs and endpoints

21 nt reduced viral titers, particularly in the lower respiratory tract, and substantially alleviated di

22 nduced by aerosol immunization targeting the lower respiratory tract, and that S-FLU is a promising u

23 Viral infections of the lower respiratory tract are a leading cause of mortality

24 Lung transplant recipients with CARVs in the lower respiratory tract are at increased risk to develop

25 ction against RSV infection in the upper and lower respiratory tract at a dose of 10(6) PFU of vaccin

26 ly defective in replication in the upper and lower respiratory tract but also triggered a strong prot

27 Infection of the lower respiratory tract by influenza A viruses results i

28 us clinical syndrome primarily affecting the lower respiratory tract, characterized by episodic or pe

29 to-treat infected population, we noted fewer lower respiratory tract complications requiring antibiot

30 linical symptom alleviation, reduces risk of lower respiratory tract complications, and admittance to

31 ized with H1N1pdm09 were more likely to have lower respiratory tract complications, shock/sepsis, and

32 (BALF) from immunocompromised subjects with lower respiratory tract disease (LRTD).

33 ll transplantation (HCT), frequently causing lower respiratory tract disease (LRTD).

34 l virus (RSV) is the leading cause of infant lower respiratory tract disease and hospitalization worl

35 ncytial virus (RSV) is a top cause of severe lower respiratory tract disease and mortality in infants

36 Lower respiratory tract disease can manifest itself as a

37 neumococcal carriage did not impact rates of lower respiratory tract disease for these 3 viruses.

38 upper respiratory tract and then progress to lower respiratory tract disease in a subset of patients.

39 (RSV) is an important pathogen causing acute lower respiratory tract disease in children.

40 al virus (RSV) is the leading viral cause of lower respiratory tract disease in infants and children

41 amyxovirus, is a major viral cause of severe lower respiratory tract disease in infants and children.

42 tial virus (hRSV) is responsible for serious lower respiratory tract disease in infants and in older

43 cytial virus (RSV) infection, a severe acute lower respiratory tract disease in infants and young chi

44 SV) is a major cause of morbidity and severe lower respiratory tract disease in the elderly and very

45 Bovine RSV (BRSV) is a primary cause of lower respiratory tract disease in young cattle.

46 syncytial virus (RSV) is a leading cause of lower respiratory tract disease in young children and el

47 atients with AERD have more severe upper and lower respiratory tract disease than do aspirin-tolerant

48 g for respiratory viruses (RVs) in suspected lower respiratory tract disease, 72 paired NP and bronch

49 children with acute respiratory failure from lower respiratory tract disease, an extubation readiness

50 syncytial virus (RSV) is a leading cause of lower respiratory tract disease, which causes high rates

51 eceiving invasive mechanical ventilation for lower respiratory tract disease.

52 children with acute respiratory failure from lower respiratory tract disease.

53 ons may explain why MERS is characterized by lower respiratory tract disease.

54 is a primary etiological agent of childhood lower respiratory tract disease.

55 A multivariate risk factor analysis of lower-respiratory tract disease (LRTD) identified 2 cond

56 e diseases (lung cancer, stroke, and chronic lower respiratory tract diseases) and examined the simul

57 p disorder, cardiovascular diseases, chronic lower respiratory tract diseases, liver cirrhosis, and s

58 as Haemophilus influenzae, a major cause of lower respiratory tract diseases, must cope with a range

59 and to assess its association with upper and lower respiratory tract disorders.

60 retion was selectively enhanced in the human lower respiratory tract during a seasonal outbreak domin

61 which samples the cellular milieu within the lower respiratory tract, has not been well studied in se

62 c plasmablasts presumably originating in the lower respiratory tract have recently been found in the

63 caques had high viral loads in the upper and lower respiratory tract, humoral and cellular immune res

64 om 524 Argentinean infants hospitalized with lower respiratory tract illness (LRTI) due to respirator

65 Viral lower respiratory tract illness (LRTI) frequently causes

66 RSV causes ~34 million new episodes of lower respiratory tract illness (LRTI) in children young

67 RSV) is the most common cause of viral acute lower respiratory tract illness (LRTI) in young children

68 Hospitalizations and deaths due to severe lower respiratory tract illness (LRTI) were recorded dur

69 ildren develop recurrent, severe episodes of lower respiratory tract illness (LRTI).

70 Immune-mediated lung injury is a hallmark of lower respiratory tract illness caused by respiratory sy

71 One hundred and fifty (29%) infants had a lower respiratory tract illness during the first year of

72 Respiratory syncytial virus (RSV) causes lower respiratory tract illness frequently.

73 Early life lower respiratory tract illness impairs lung function at

74 RATIONALE: Lower respiratory tract illness is a major cause of chil

75 Preventing early life lower respiratory tract illness is important to optimize

76 mens from participants presenting with acute lower respiratory tract illness or acute febrile illness

77 Lower respiratory tract illness surveillance was perform

78 Lower respiratory tract illness was independently associ

79 often manifested as severe, life-threatening lower respiratory tract illness with high rates of pneum

80 disease 2019 (COVID-19), a recently emerged lower respiratory tract illness, has quickly become a pa

81 he impact of early life exposures, including lower respiratory tract illness, on lung function during

82 and protection from virus replication in the lower respiratory tract.IMPORTANCE RSV disease is of gre

83 itionally associated with specimens from the lower respiratory tract in adults.

84 stent wheeze or asthma and infections of the lower respiratory tract in offspring by approximately 7

85 uction of viral replication in the upper and lower respiratory tracts in nonhuman primates(11-13).

86 should elicit mucosal immunity at upper and lower respiratory tracts in order to most effectively pr

87 n the upper respiratory tract and not in the lower respiratory tract, including lung.

88 is among the most important causes of acute lower respiratory tract infection (ALRI) in young childr

89 infant hospitalizations for all-cause acute lower respiratory tract infection (ALRI).

90 that can predict the risk of progression to lower respiratory tract infection (LRTI) and RSV-associa

91 that there is no effective treatment for RSV lower respiratory tract infection (LRTI) and that suppor

92 er clinical trial of the FDA-cleared Unyvero lower respiratory tract infection (LRTI) application (Cu

93 Lower respiratory tract infection (LRTI) commonly causes

94 ated with respiratory failure (RF) and fatal lower respiratory tract infection (LRTI) in premature ch

95 Distinguishing between bacterial and viral lower respiratory tract infection (LRTI) remains challen

96 Previous pulmonary tuberculosis (PTB) or lower respiratory tract infection (LRTI) was significant

97 cumented pneumonia, and secondary outcome, a lower respiratory tract infection (LRTI) without radiogr

98 r respiratory tract infection (URTI) without lower respiratory tract infection (LRTI), URTI progressi

99 e most common reason for hospitalization was lower respiratory tract infection (LRTI).

100 al significance remains unclear in pediatric lower respiratory tract infection (LRTI).

101 is to 5.84 (95% CI 5.61-6.08; p < 0.001) for lower respiratory tract infection (LRTI).

102 on (SSI), urinary tract infection (UTI), and lower respiratory tract infection (LRTI).

103 RSV-confirmed hospitalizations or outpatient lower respiratory tract infection (LRTI).

104 Pneumonia (n=5 [5%]) and lower respiratory tract infection (n=4 [4%]) were consid

105 The most common serious adverse events were lower respiratory tract infection (n=7 [7%]), pneumonia

106 egalovirus (CMV) antigenemia (p = 0.005) and lower respiratory tract infection (p = 0.003) and no leu

107 yncytial virus (RSV) is the leading cause of lower respiratory tract infection among infants and youn

108 tory syncytial virus is the leading cause of lower respiratory tract infection among infants.

109 d for 180 days to assess outcomes related to lower respiratory tract infection and for 364 days to as

110 leading viral pathogen associated with acute lower respiratory tract infection and hospitalization in

111 cimens from patients hospitalized with acute lower respiratory tract infection and identified factors

112 It is a major cause of acute lower respiratory tract infection and is associated with

113 ered by elective CS had an increased risk of lower respiratory tract infection and juvenile idiopathi

114 specific patterns of AWaRe antibiotic use in lower respiratory tract infection and neonatal sepsis we

115 eneralisable, causal association between RSV lower respiratory tract infection and subsequent long-te

116 ealthier fashion as regards risk factors for lower respiratory tract infection and there is evidence

117 ne candidates were efficacious in preventing lower respiratory tract infection as well as in reducing

118 Human respiratory syncytial virus (RSV) lower respiratory tract infection can result in inflamma

119 Lower respiratory tract infection contributed to 174 (57

120 Mortality from lower respiratory tract infection fell as cognitive abil

121 ps between neonatal interferon responses and lower respiratory tract infection history during infancy

122 he effects of oral corticosteroids for acute lower respiratory tract infection in adults without asth

123 syncytial virus (RSV) is the major cause of lower respiratory tract infection in children worldwide.

124 behind, although hMPV is a leading cause of lower respiratory tract infection in children.

125 eumovirus (hMPV) is a leading cause of viral lower respiratory tract infection in children.

126 sevimab for the prevention of RSV-associated lower respiratory tract infection in healthy infants who

127 infection is a leading cause of severe acute lower respiratory tract infection in infants and childre

128 cytial virus (RSV) is a significant cause of lower respiratory tract infection in infants and elderly

129 gainst RSV-associated, medically significant lower respiratory tract infection in infants up to 90 da

130 tial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need

131 ial virus (hRSV) is a leading cause of acute lower respiratory tract infection in infants, elderly an

132 virus (RSV) is the dominant cause of severe lower respiratory tract infection in infants, with the m

133 al virus (RSV) is the most frequent cause of lower respiratory tract infection in infants.

134 alog, efficiently inhibits established acute lower respiratory tract infection in the animals, even w

135 R-confirmed COVID-19 adults with symptoms of lower respiratory tract infection in the emergency depar

136 syncytial virus (RSV) is a leading cause of lower respiratory tract infection in young children worl

137 ry syncytial virus is a major cause of acute lower respiratory tract infection in young children, imm

138 ococcus pneumoniae, the transition to severe lower respiratory tract infection is associated with an

139 Acute lower respiratory tract infection is common and often tr

140 Respiratory syncytial virus (RSV) lower respiratory tract infection is implicated in asthm

141 and increased dissemination to blood in the lower respiratory tract infection model.

142 corticosteroids should not be used for acute lower respiratory tract infection symptoms in adults wit

143 rved for duration or severity of other acute lower respiratory tract infection symptoms, duration of

144 outcomes were duration and severity of acute lower respiratory tract infection symptoms, duration of

145 point was medically attended RSV-associated lower respiratory tract infection through 150 days after

146 point was hospitalization for RSV-associated lower respiratory tract infection through 150 days after

147 nt was RSV-associated, medically significant lower respiratory tract infection up to 90 days of life,

148 s with RSV-associated, medically significant lower respiratory tract infection was 1.5% in the vaccin

149 cidence of medically attended RSV-associated lower respiratory tract infection was 70.1% lower (95% c

150 idence of hospitalization for RSV-associated lower respiratory tract infection was 78.4% lower (95% C

151 tages for hospitalization for RSV-associated lower respiratory tract infection were 2.1% and 3.7% (va

152 s who had been admitted to a hospital with a lower respiratory tract infection with a pneumonia index

153 corresponding percentages for RSV-associated lower respiratory tract infection with severe hypoxemia

154 deficient (PAD) patients, 4 (5%) adults with lower respiratory tract infection, 1 (2.6%) sputum sampl

155 nts judged reasonably related to siltuximab (lower respiratory tract infection, anaphylactic reaction

156 ix [12%]), febrile neutropenia (five [10%]), lower respiratory tract infection, and pneumonia (each t

157 Dementia increases the risk of lower respiratory tract infection, but it is unclear whe

158 aged >60 yr) patients in health and during a lower respiratory tract infection, community-acquired pn

159 are typically young children with upper and lower respiratory tract infection, presenting with sympt

160 d intratracheal routes to cause an upper and lower respiratory tract infection, respectively.

161 upper respiratory tract infection to severe lower respiratory tract infection, that can lead to diff

162 g treated with intravenous ceftriaxone for a lower respiratory tract infection, thereby supporting co

163 he epithelial secretome participating in RSV lower respiratory tract infection-induced airway remodel

164 ognitive ability increase risk of dying from lower respiratory tract infection.

165 between cognitive ability and mortality from lower respiratory tract infection.

166 nts that resulted in two bacteremias and one lower respiratory tract infection.

167 ed paramyxovirus that causes acute upper and lower respiratory tract infection.

168 to develop respiratory syncytial virus acute lower respiratory tract infection.Respiratory syncytial

169 ome (MERS) coronavirus causes a highly fatal lower-respiratory tract infection.

170 .25]; two studies, 1 681 020 events) and for lower respiratory tract infections (-18.48% [-32.79 to -

171 nfection (343 [45%] infections), followed by lower respiratory tract infections (171 [22%]), gastroin

172 g children worldwide, commonly through acute lower respiratory tract infections (ALRI).

173 monia among patients hospitalized with acute lower respiratory tract infections (ALRTIs).

174 Virus-associated febrile lower respiratory tract infections (fLRIs) during infanc

175 Lower respiratory tract infections (LRTIs) are a leading

176 Lower respiratory tract infections (LRTIs) are a persist

177 ry syncytial virus (RSV) and rhinovirus (RV) lower respiratory tract infections (LRTIs) being strongl

178 Childhood lower respiratory tract infections (LRTIs) cause substan

179 per respiratory tract infections (URTIs) and lower respiratory tract infections (LRTIs) was collected

180 logical pathogen in hospitalized adults with lower respiratory tract infections (LRTIs).

181 In contrast, non-CAAP lower respiratory tract infections (NA-LRI) are generall

182 In contrast, non-CAAP lower respiratory tract infections (NA-LRIs) are general

183 rdant in uncomplicated urinary and upper and lower respiratory tract infections (RTIs).

184 We assessed the seasonality of viral lower respiratory tract infections (V-LRI), bacteremic p

185 ry syncytial virus (RSV) is a major cause of lower respiratory tract infections and hospital visits d

186 al virus (RSV) is the leading cause of acute lower respiratory tract infections and hospitalizations

187 d in fewer medically attended RSV-associated lower respiratory tract infections and hospitalizations

188 spiratory syncytial virus (RSV) causes acute lower respiratory tract infections and is the leading ca

189 spectrum antibiotics and those admitted with lower respiratory tract infections and skin and soft tis

190 spectrum antibiotics and those admitted with lower respiratory tract infections and skin and soft tis

191 Although non-CAAP lower respiratory tract infections are usually not consi

192 children hospitalized at one institution for lower respiratory tract infections between January 1, 20

193 Lower respiratory tract infections by respiratory syncyt

194 ly identification of the causative agents of lower respiratory tract infections can promote better pa

195 Lower respiratory tract infections caused by bacteria ar

196 Airway inflammation is a critical feature of lower respiratory tract infections caused by viruses suc

197 association study and subsequent symptoms of lower respiratory tract infections during the first year

198 Lower respiratory tract infections from respiratory sync

199 ortant cause of otitis media in children and lower respiratory tract infections in adults with chroni

200 al virus (RSV) is a major cause of upper and lower respiratory tract infections in children for which

201 irus (RSV) is the leading etiologic agent of lower respiratory tract infections in children, but no l

202 virus (hRSV) is the leading cause of severe lower respiratory tract infections in children.

203 tial virus (RSV) is a leading cause of acute lower respiratory tract infections in children.

204 syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children.

205 e susceptibility and exaggerated response to lower respiratory tract infections in general rather tha

206 yncytial virus (RSV) is the leading cause of lower respiratory tract infections in infant and elderly

207 irus (RSV) is the most common cause of viral lower respiratory tract infections in infants and childr

208 hRSV is a leading cause of lower respiratory tract infections in infants and young

209 yncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants, a safe an

210 ed RNA genome viruses, is a leading cause of lower respiratory tract infections in infants, young chi

211 virus (RSV) is a major cause of severe acute lower respiratory tract infections in infants.

212 syncytial virus (RSV) can cause devastating lower respiratory tract infections in preterm infants or

213 Lower respiratory tract infections in the first years of

214 yncytial virus (RSV) is the leading cause of lower respiratory tract infections in the very young.

215 RSV is a major cause of serious lower respiratory tract infections in young children and

216 is an emerging respiratory virus that causes lower respiratory tract infections in young children wor

217 a single-stranded DNA parvovirus that causes lower respiratory tract infections in young children wor

218 avirus 1 (HBoV1), a human parvovirus, causes lower respiratory tract infections in young children.

219 y syncytial virus (RSV) is the main cause of lower respiratory tract infections in young children.

220 ore T1/3IFNs, whereas risk for infant wheezy lower respiratory tract infections or "transient early w

221 99.6% of in-county children hospitalized for lower respiratory tract infections were admitted to Cinc

222 ratory infections (comprising both upper and lower respiratory tract infections with viruses, bacteri

223 with confirmed RSV ARTI (includes upper and lower respiratory tract infections), 500 without and 50

224 s upper respiratory tract infections, severe lower respiratory tract infections, and exacerbations of

225 sthma, and the secondary end points included lower respiratory tract infections, asthma exacerbations

226 RSV), a human pathogen that can cause severe lower respiratory tract infections, especially in infant

227 Lower respiratory tract infections, including hospital-a

228 erved CD4 cell counts are at higher risk for lower respiratory tract infections, indicating impaired

229 nts treated with intravenous ceftriaxone for lower respiratory tract infections, oral ribaxamase redu

230 They often precede serious lower respiratory tract infections.

231 n 83 hospitalized patients <2 years old with lower respiratory tract infections.

232 etiologic association in persons with severe lower respiratory tract infections.

233 ure-positive and culture-negative sepsis and lower respiratory tract infections.

234 e of particular concern in the management of lower respiratory tract infections.

235 ainfluenza virus (PIV) is a leading cause of lower respiratory tract infections.

236 e prevention of medically attended RSV acute lower respiratory tract infections.

237 recommendations for targets in children with lower respiratory tract infections.

238 th respiratory syncytial virus (RSV)-induced lower respiratory tract infections.

239 urate method for detection of pathogens from lower respiratory tract infections.

240 PV) is a major causative agent of upper- and lower-respiratory-tract infections in infants, the elder

241 e burden and is the leading cause of serious lower-respiratory-tract infections in young children.

242 upper respiratory tract infectious disease, lower respiratory tract infectious disease (LRTID), or a

243 ssessed in three murine models of infection: lower respiratory tract (intranasal challenge of 1 x 10(

244 The secretion of this protease in the human lower respiratory tract is enhanced during influenza.

245 bial-resistant pneumococci isolated from the lower respiratory tract (LRT) of adults.

246 The Unyvero lower respiratory tract (LRT) panel (Curetis, Holzgerlin

247 t (URT), but the concordance between URT and lower respiratory tract (LRT) RV detection is not well c

248 sensor kinase, PlrS [for persistence in the lower respiratory tract (LRT) sensor], which is required

249 Comprehensive molecular testing of single lower respiratory tract (LRT) specimens achieved pathoge

250 he lungs affect bacterial replication in the lower respiratory tract (LRT).

251 Mucosal immune mechanisms in the upper and lower respiratory tracts may serve a critical role in pr

252 to assess the concordance between upper and lower respiratory tract microbiota during LRTIs and the

253 al microbiota can serve as a valid proxy for lower respiratory tract microbiota in childhood LRTIs, t

254 /13 virus led to productive infection of the lower respiratory tract of guinea pigs.

255 ory tract (nasal turbinates) but also in the lower respiratory tract of infected mice, with a peak at

256 ed the ability of the mutant to colonize the lower respiratory tract of mice.

257 D locus was found to enhance survival in the lower respiratory tract of swine.

258 tes of MERS-CoV replication in the upper and lower respiratory tracts of camels and humans, respectiv

259 ruses was highly attenuated in the upper and lower respiratory tracts of cotton rats.

260 uses replicated efficiently in the upper and lower respiratory tracts of ferrets; however, the clinic

261 eplicated productively in both the upper and lower respiratory tracts of guinea pigs, similarly to vi

262 or replication in vitro and in the upper and lower respiratory tracts of hamsters: this was not influ

263 lture and viral replication in the upper and lower respiratory tracts of specific-pathogen-free (SPF)

264 se with decreasing expression throughout the lower respiratory tract, paralleled by a striking gradie

265 syncytial virus (RSV) is the most important lower respiratory tract pathogen of infants for which th

266 , viruses, and fungi from both the upper and lower respiratory tract produce structural ligands and m

267 Confirmation of RSV infection in the lower respiratory tract provides prognostic information

268 in the relatively sterile environment of the lower respiratory tract, rather than in the upper respir

269 Finally, the dissociation between upper and lower respiratory tract results underscores the need for

270 criteria were (a) positive nasopharyngeal or lower respiratory tract reverse transcriptase polymerase

271 LRTI was defined as a positive lower respiratory tract sample with or without radiograp

272 Lower respiratory tract samples yield significantly high

273 zero by day 30, and is highest in feces and lower respiratory tract samples.

274 sequencing techniques in the examination of lower respiratory tract samples.

275 the other human coronaviruses targeting the lower respiratory tract - severe acute respiratory syndr

276 (PMN) cells are regarded as indicative of a lower respiratory tract specimen.

277 el (BFPP) for identification of pathogens in lower respiratory tract specimens (n = 200) from emergen

278 d antimicrobial resistance marker genes from lower respiratory tract specimens (sputum and bronchoalv

279 tified 6 HCT recipients with BoV detected in lower respiratory tract specimens [incidence rate of 0.4

280 Classical P1-2 was more frequent in lower respiratory tract specimens and had longer p1 trin

281 n abnormalities, and Legionella detection in lower respiratory tract specimens by culture and/or real

282 eview of HCT recipients with BoV detected in lower respiratory tract specimens.

283 1 RNA was quantified in available upper- and lower-respiratory tract specimens as well as fecal and b

284 Respiratory viruses in upper- and/or lower-respiratory tract specimens were tested using mult

285 ce was assessed using 483 remnant upper- and lower-respiratory-tract specimens previously analyzed by

286 ion of SARS-CoV-2 in a variety of upper- and lower-respiratory-tract specimens.

287 g 401 adults with acute cough and at least 1 lower respiratory tract symptom not requiring immediate

288 The primary outcome for both trials compared lower respiratory tract symptoms (LRTSs) between study g

289 traditionally develop significant upper and lower respiratory tract symptoms on ingestion of cycloxg

290 ulation, 6.2% to 13.4%) children experienced lower respiratory tract symptoms within 72 hours, includ

291 of RV infections, and propensity to develop lower respiratory tract symptoms.

292 nza A(H7N9) could replicate in the upper and lower respiratory tract, the heart, the liver, and the o

293 load in the bronchoalveolar lavage fluid and lower respiratory tract tissue of vaccinated rhesus maca

294 reat infections, most commonly involving the lower respiratory tract, urinary tract, or skin and soft

295 The lower respiratory tract was once thought to be a sanctua

296 n participants, the levels of ADAMTS4 in the lower respiratory tract were associated with the severit

297 rrespondingly, viral titers in the upper-and lower-respiratory tract were reduced only in piglets tha

298 accurately reflect etiologic agents from the lower respiratory tract where sputum specimens are consi

299 esized that a specimen representative of the lower respiratory tract will contain smaller quantities

300 n of CD151 in IAV infection of the upper and lower respiratory tracts with H1N1 and H3N2 strains.